QuickView: Solving ophthalmic gene therapy

Avalanche is well capitalised to deliver all important proof-of-concept data in 2015 with trial readout in wet AMD. By combining its gene therapy technology platform with vascular endothelial growth factor (VEGF) trap molecules, Avalanche is aiming to break into the $6bn exudative AMD market. With $290m in cash and a Regeneron licensing deal for orphan diseases, Avalanche is well placed to deliver on its clinical programmes.